logo
  Join        Login             Stock Quote

Lpath Receives First U.S. Patent for Anti-LPA Antibody, Lpathomab

Wednesday, April 25, 2012 8:31 AM


http://media.marketwire.com/attachments/200903/512458_Lpath-New-Logo-2.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=878782&ProfileId=051205&sourceType=1

SAN DIEGO, CA -- (Marketwire) -- 04/25/12 -- Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent protecting Lpathomab™, a monoclonal antibody against lysophosphatidic acid (LPA).

The newly issued U.S. Patent No. 8,158,124 claims antibody compositions directed against LPA, a bioactive lipid that has been validated as a target in multiple disease states.

"The issuance of our first Lpathomab patent is a major milestone for Lpath and an essential step in the product's development," stated Roger Sabbadini, Lpath's founder, chief science officer and an inventor on the patent. "It provides further protection for our drug-development program that promises to solve important unmet clinical needs."

LPA is a well-validated drug target: peer-reviewed journals have established that LPA promotes tumorigenesis, metastasis and fibrotic disease and plays a significant role in neuropathic pain and in neurotrauma, including traumatic brain injury (TBI) and spinal cord injury (SCI).

Lpath and collaborators have recently shown that Lpathomab provides protection against neuronal cell death in TBI and SCI studies, where size of the injury was reduced after TBI; and behavioral function was improved after both TBI and SCI. Future studies will be directed toward examining Lpathomab's activity against a range of CNS disorders in which cell death is observed, including Alzheimer's disease and other neurodegenerative diseases.

Scott Pancoast, Lpath's president and CEO, commented: "The issuance of a composition-of-matter patent for an anti-LPA antibody significantly enhances the commercial value of our Lpathomab program. The LPA signaling pathway has been well implicated as a contributor to disease progression, and while others are intervening downstream at the LPA-receptor level, we believe the direct approach of neutralizing LPA itself has certain advantages that will prove out over time."

Lpathomab was generated using Lpath's proprietary ImmuneY2™ technology.


Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.